2025 Q2 -tulosraportti
105 päivää sittenTarjoustasot
Oslo Børs
Määrä
Osto
621
Myynti
Määrä
69 445
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 500 | - | - | ||
| 3 000 | - | - | ||
| 55 | - | - | ||
| 40 | - | - | ||
| 1 562 | - | - |
Ylin
4,18VWAP
Alin
4,135VaihtoMäärä
0,8 194 612
VWAP
Ylin
4,18Alin
4,135VaihtoMäärä
0,8 194 612
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 H1 -tulosraportti | 29.8. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q2 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23 t sittenI have followed Thor Medical (TRMED) quite closely throughout the year, and even though this is not investment advice, I want to share why I believe the stock appears cheap and potentially a New Year's rocket if several catalysts materialize. As of today (December 11, 2025), the share price is around 4,1 kroner per share, and many may not have fully priced in the value creation that lies ahead for the company. The price has seen a steady increase from around 2–2,5 kroner earlier in the year, but the big momentum could still be ahead of us. Source: getagraph market data. The company has undergone several important milestones in 2025. The pilot plant at Herøya, which became operational in Q4 2024, has delivered product samples of good quality, and customers have confirmed this. This has led to commercial agreements with several players in the radiopharma market. Source: annual report 2024 and 1H 2025 report. The biggest catalyst is undoubtedly AlphaOne, the company's first commercial production facility for alpha-emitters, which is now under construction with the start of commercial production planned for Q3 2026. This facility is being built with an investment of approx. NOK 200 million and is planned to deliver production volumes that will generate good top-line revenue and cash flow. Source: AlphaOne press release. AlphaOne already has multi-year supply agreements in place, and production is largely pre-booked through these agreements. The company has also entered into strategic agreements for the supply of raw material (feedstock) for the production of thorium, which provides a more secure value chain. Source: TRMED press releases. During 2025, Thor Medical has also signed a strategic agreement with Oncoinvent, where Thor Medical will supply Thorium-228 for clinical programs, and an extended agreement with AdvanCell, which increases the commitment for the supply of isotopes. Source: TRMED press releases. In addition, the company conducted a private placement and retail offering in the summer of 2025 to finance expanded capacity in AlphaOne. Source: stock exchange announcement June 2025. All of this means that Thor Medical is transitioning from being a pure research/pilot case to being a player with commercial production within a rapidly growing market. Radioligand therapy is growing globally, and in the long term, the demand for alpha isotopes such as Thorium-228 and Pb-212 could become significantly greater than what the market can currently supply. This offers interesting asymmetric potential if AlphaOne succeeds as planned. Of course, there is risk: the stock is still in a development phase and is not yet earning significant money. Any delays in construction, technical challenges, or the need for new capital could negatively impact the share price in the short term. It is also discussed on various market forums that the case is still premature for many investors, even though the fundamentals seem stronger than before. Source: discussions in market forums. For my part, this gives me confidence that today's price may be low compared to what could happen in the next 6–12 months, especially as AlphaOne approaches production start and revenues begin to materialize. Again: these are my personal assessments, not investment advice. When I look at the whole picture, I can't quite decide if I'm naive or if the market is actually severely underestimating the case. Several of the agreements, the progress at Herøya, and the strategic position in a growing radioligand market make me lean towards the stock being mispriced. At the same time, it is clear that some investors are sitting on the fence, waiting for more tangible earnings before daring to enter. That's precisely why I'm curious: what do you others think? Am I too optimistic, or is this a case that the market hasn't truly woken up to yet?
·15 t sittenThe argument that the risk lies in the customer's success is a bit backward. The customers Thor delivers to are already in the market, already operational, and already have demand. When Alpha One is switched on, everything is about how much Thor can actually produce. This is a supply problem, not a customer problem.·5 t sittenIt's perfectly fine to read up on the product itself without looking at Thor as a company. I think many would be surprised by how enormous the demand actually is. I would be more concerned about access to resources than about Thor's customer portfolio. Now that they have entered into a strategic collaboration with Norway via Fensfeltet, that's where I think the real key lies. Hope it bears fruit. A factory is to be built and things need to run smoothly, so of course there is risk, but not biotech risk as an incredible number of people in here seem to believe.
·1 päivä sitten·1 päivä sittenDon't have access, do you have a short summary?
·1 päivä sitten«Cup with a handle» is appearing more and more here 🥰
·2 päivää sittenI guess many come up with revised theories during the day 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
105 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenI have followed Thor Medical (TRMED) quite closely throughout the year, and even though this is not investment advice, I want to share why I believe the stock appears cheap and potentially a New Year's rocket if several catalysts materialize. As of today (December 11, 2025), the share price is around 4,1 kroner per share, and many may not have fully priced in the value creation that lies ahead for the company. The price has seen a steady increase from around 2–2,5 kroner earlier in the year, but the big momentum could still be ahead of us. Source: getagraph market data. The company has undergone several important milestones in 2025. The pilot plant at Herøya, which became operational in Q4 2024, has delivered product samples of good quality, and customers have confirmed this. This has led to commercial agreements with several players in the radiopharma market. Source: annual report 2024 and 1H 2025 report. The biggest catalyst is undoubtedly AlphaOne, the company's first commercial production facility for alpha-emitters, which is now under construction with the start of commercial production planned for Q3 2026. This facility is being built with an investment of approx. NOK 200 million and is planned to deliver production volumes that will generate good top-line revenue and cash flow. Source: AlphaOne press release. AlphaOne already has multi-year supply agreements in place, and production is largely pre-booked through these agreements. The company has also entered into strategic agreements for the supply of raw material (feedstock) for the production of thorium, which provides a more secure value chain. Source: TRMED press releases. During 2025, Thor Medical has also signed a strategic agreement with Oncoinvent, where Thor Medical will supply Thorium-228 for clinical programs, and an extended agreement with AdvanCell, which increases the commitment for the supply of isotopes. Source: TRMED press releases. In addition, the company conducted a private placement and retail offering in the summer of 2025 to finance expanded capacity in AlphaOne. Source: stock exchange announcement June 2025. All of this means that Thor Medical is transitioning from being a pure research/pilot case to being a player with commercial production within a rapidly growing market. Radioligand therapy is growing globally, and in the long term, the demand for alpha isotopes such as Thorium-228 and Pb-212 could become significantly greater than what the market can currently supply. This offers interesting asymmetric potential if AlphaOne succeeds as planned. Of course, there is risk: the stock is still in a development phase and is not yet earning significant money. Any delays in construction, technical challenges, or the need for new capital could negatively impact the share price in the short term. It is also discussed on various market forums that the case is still premature for many investors, even though the fundamentals seem stronger than before. Source: discussions in market forums. For my part, this gives me confidence that today's price may be low compared to what could happen in the next 6–12 months, especially as AlphaOne approaches production start and revenues begin to materialize. Again: these are my personal assessments, not investment advice. When I look at the whole picture, I can't quite decide if I'm naive or if the market is actually severely underestimating the case. Several of the agreements, the progress at Herøya, and the strategic position in a growing radioligand market make me lean towards the stock being mispriced. At the same time, it is clear that some investors are sitting on the fence, waiting for more tangible earnings before daring to enter. That's precisely why I'm curious: what do you others think? Am I too optimistic, or is this a case that the market hasn't truly woken up to yet?·15 t sittenThe argument that the risk lies in the customer's success is a bit backward. The customers Thor delivers to are already in the market, already operational, and already have demand. When Alpha One is switched on, everything is about how much Thor can actually produce. This is a supply problem, not a customer problem.·5 t sittenIt's perfectly fine to read up on the product itself without looking at Thor as a company. I think many would be surprised by how enormous the demand actually is. I would be more concerned about access to resources than about Thor's customer portfolio. Now that they have entered into a strategic collaboration with Norway via Fensfeltet, that's where I think the real key lies. Hope it bears fruit. A factory is to be built and things need to run smoothly, so of course there is risk, but not biotech risk as an incredible number of people in here seem to believe.
- ·1 päivä sitten·1 päivä sittenDon't have access, do you have a short summary?
- ·1 päivä sitten«Cup with a handle» is appearing more and more here 🥰
- ·2 päivää sittenI guess many come up with revised theories during the day 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
621
Myynti
Määrä
69 445
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 500 | - | - | ||
| 3 000 | - | - | ||
| 55 | - | - | ||
| 40 | - | - | ||
| 1 562 | - | - |
Ylin
4,18VWAP
Alin
4,135VaihtoMäärä
0,8 194 612
VWAP
Ylin
4,18Alin
4,135VaihtoMäärä
0,8 194 612
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 H1 -tulosraportti | 29.8. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q2 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
2025 Q2 -tulosraportti
105 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 26.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2 -tulosraportti | 29.8. | |
| 2025 H1 -tulosraportti | 29.8. | |
| 2024 Q4 -tulosraportti | 26.2. | |
| 2024 H2 -tulosraportti | 26.2. | |
| 2024 Q2 -tulosraportti | 30.8.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23 t sittenI have followed Thor Medical (TRMED) quite closely throughout the year, and even though this is not investment advice, I want to share why I believe the stock appears cheap and potentially a New Year's rocket if several catalysts materialize. As of today (December 11, 2025), the share price is around 4,1 kroner per share, and many may not have fully priced in the value creation that lies ahead for the company. The price has seen a steady increase from around 2–2,5 kroner earlier in the year, but the big momentum could still be ahead of us. Source: getagraph market data. The company has undergone several important milestones in 2025. The pilot plant at Herøya, which became operational in Q4 2024, has delivered product samples of good quality, and customers have confirmed this. This has led to commercial agreements with several players in the radiopharma market. Source: annual report 2024 and 1H 2025 report. The biggest catalyst is undoubtedly AlphaOne, the company's first commercial production facility for alpha-emitters, which is now under construction with the start of commercial production planned for Q3 2026. This facility is being built with an investment of approx. NOK 200 million and is planned to deliver production volumes that will generate good top-line revenue and cash flow. Source: AlphaOne press release. AlphaOne already has multi-year supply agreements in place, and production is largely pre-booked through these agreements. The company has also entered into strategic agreements for the supply of raw material (feedstock) for the production of thorium, which provides a more secure value chain. Source: TRMED press releases. During 2025, Thor Medical has also signed a strategic agreement with Oncoinvent, where Thor Medical will supply Thorium-228 for clinical programs, and an extended agreement with AdvanCell, which increases the commitment for the supply of isotopes. Source: TRMED press releases. In addition, the company conducted a private placement and retail offering in the summer of 2025 to finance expanded capacity in AlphaOne. Source: stock exchange announcement June 2025. All of this means that Thor Medical is transitioning from being a pure research/pilot case to being a player with commercial production within a rapidly growing market. Radioligand therapy is growing globally, and in the long term, the demand for alpha isotopes such as Thorium-228 and Pb-212 could become significantly greater than what the market can currently supply. This offers interesting asymmetric potential if AlphaOne succeeds as planned. Of course, there is risk: the stock is still in a development phase and is not yet earning significant money. Any delays in construction, technical challenges, or the need for new capital could negatively impact the share price in the short term. It is also discussed on various market forums that the case is still premature for many investors, even though the fundamentals seem stronger than before. Source: discussions in market forums. For my part, this gives me confidence that today's price may be low compared to what could happen in the next 6–12 months, especially as AlphaOne approaches production start and revenues begin to materialize. Again: these are my personal assessments, not investment advice. When I look at the whole picture, I can't quite decide if I'm naive or if the market is actually severely underestimating the case. Several of the agreements, the progress at Herøya, and the strategic position in a growing radioligand market make me lean towards the stock being mispriced. At the same time, it is clear that some investors are sitting on the fence, waiting for more tangible earnings before daring to enter. That's precisely why I'm curious: what do you others think? Am I too optimistic, or is this a case that the market hasn't truly woken up to yet?·15 t sittenThe argument that the risk lies in the customer's success is a bit backward. The customers Thor delivers to are already in the market, already operational, and already have demand. When Alpha One is switched on, everything is about how much Thor can actually produce. This is a supply problem, not a customer problem.·5 t sittenIt's perfectly fine to read up on the product itself without looking at Thor as a company. I think many would be surprised by how enormous the demand actually is. I would be more concerned about access to resources than about Thor's customer portfolio. Now that they have entered into a strategic collaboration with Norway via Fensfeltet, that's where I think the real key lies. Hope it bears fruit. A factory is to be built and things need to run smoothly, so of course there is risk, but not biotech risk as an incredible number of people in here seem to believe.
- ·1 päivä sitten·1 päivä sittenDon't have access, do you have a short summary?
- ·1 päivä sitten«Cup with a handle» is appearing more and more here 🥰
- ·2 päivää sittenI guess many come up with revised theories during the day 😅
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
621
Myynti
Määrä
69 445
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 500 | - | - | ||
| 3 000 | - | - | ||
| 55 | - | - | ||
| 40 | - | - | ||
| 1 562 | - | - |
Ylin
4,18VWAP
Alin
4,135VaihtoMäärä
0,8 194 612
VWAP
Ylin
4,18Alin
4,135VaihtoMäärä
0,8 194 612
Välittäjätilasto
Dataa ei löytynyt